Profil bibliographique

Diamant Thaçi

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

716Publications signalées

24192Citations signalées

4Affiliations récentes

Institutions déclarées

Novartis (Switzerland)Institute for Integrative and Experimental Genomics Centre for Inflammation Research University of Lübeck

Domaines associés

Psoriasis: Treatment and PathogenesisDermatology and Skin DiseasesSpondyloarthritis Studies and TreatmentsAsthma and respiratory diseasesAutoimmune Bullous Skin Diseases

Publications récentes

Accès ouvert 2026 articleOpenAlex

Glucagon-like peptide-1 receptor agonists and tirzepatide are associated with reduced mortality, cardiovascular, and psychiatric risks in patients with hidradenitis suppurativa and type 2 diabetes and/or obesity: a retrospective cohort study

Inga C. Brouer, Aida Zani, Henning Olbrich, Ralf J. Ludwig et autres

0 citationsFrontiers in Medicine

Accès ouvert 2026 erratumOpenAlex

Correction: Three-Year Efficacy and Safety of Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Long-Term Extension (ADjoin)

Emma Guttman-Yassky, Alan D. Irvine, Melinda Gooderham, Stephan Weidinger et autres

0 citationsDermatology and Therapy

Accès ouvert 2026 articleOpenAlex

Real-world effectiveness and safety of 12 months of tralokinumab in patients with atopic dermatitis

Adis journals on behalf of:, April W Armstrong, ahmed ameen, Silvia Ferrucci et autres

0 citationsFigshare

Accès ouvert 2026 articleOpenAlex

Real-world effectiveness and safety of 12 months of tralokinumab in patients with atopic dermatitis

Adis journals on behalf of:, April W Armstrong, ahmed ameen, Silvia Ferrucci et autres

0 citationsFigshare

Accès ouvert 2026 articleOpenAlex

Real-World Effectiveness and Safety of 12 Months of Tralokinumab in Patients with Atopic Dermatitis

April W. Armstrong, Ahmed Ameen, Silvia Ferrucci, José-Juan Pereyra-Rodríguez et autres

0 citationsDermatology and Therapy

Accès ouvert 2026 articleOpenAlex

Skewed MHC Class I Peptide Presentation in Psoriatic Arthritis

Sara Comdühr, Thorben Sauer, Silja Deckert, Silke Pitann et autres

0 citationsInternational Journal of Molecular Sciences

Accès ouvert 2026 articleOpenAlex

Deucravacitinib 5-Year Safety and Efficacy Results in Plaque Psoriasis: A Phase 3 Open-Label Extension of Randomized Clinical Trials

April W. Armstrong, Mark Lebwohl, Richard B. Warren, Akimichi Morita et autres

0 citationsAmerican Journal of Clinical Dermatology

2026 articleOpenAlex

Rezpegaldesleukin treatment of moderate-to-severe atopic dermatitis (REZOLVE-AD): final results from the 16-week induction period of an international, double-blind, placebo-controlled, randomised phase 2b study

Jonathan I Silverberg, David Rosmarin, Thomas Bieber, Raj Chovatiya et autres

0 citationsThe Lancet

Accès ouvert 2026 articleOpenAlex

Risk of Adverse Pregnancy Outcomes in Patients with Non-Communicable, Chronic Inflammatory Barrier Diseases Under Systemic Treatment: A Large-Scale Retrospective Cohort Study

Inga Catharina Brouer, Aida Zani, Philip Curman, Ralf J. Ludwig et autres

0 citationsBiomolecules

2026 articleOpenAlex

Deucravacitinib in Active Psoriatic Arthritis: Efficacy and Safety up to 52 Weeks From the Randomized, Double‐Blind, Phase 3 POETYK PsA‐2 Trial

Philip J. Mease, Vinod Chandran, April W. Armstrong, Ricardo Blanco et autres

2 citationsArthritis & Rheumatology

Accès ouvert 2026 articleOpenAlex

Psychiatric Risk in Chronic Spontaneous Urticaria: A Retrospective Cohort Study

Philip Curman, Henning Olbrich, Khalaf Kridin, Diamant Thaçi et autres

0 citationsActa Dermato Venereologica

2026 articleOpenAlex

76707 Continuous response with nemolizumab - Efficacy and safety up to 104 weeks in patients with moderate-to-severe atopic dermatitis with partial and non-response in skin at 16 weeks: Post hoc analyses from the ARCADIA LTE trial

Jonathan I. Silverberg, Linda Stein-Gold, Diamant Thaçi, Andrew E. Pink et autres

0 citationsJournal of the American Academy of Dermatology

Profil ORCID Notice OpenAlex

BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.